AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 307.4 USD | +0.51% |
|
+0.52% | +6.74% |
| 05-28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
| 05-28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 33B 2,576B | Sales 2025 * | 33.96B 2,651B | Capitalization | 164B 12,808B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B 323B | Net income 2025 * | 6.52B 509B | EV / Sales 2024 * | 6.44 x |
| Net Debt 2024 * | 48.6B 3,794B | Net Debt 2025 * | 43.61B 3,405B | EV / Sales 2025 * | 6.12 x |
| P/E ratio 2024 * |
38.6
x | P/E ratio 2025 * |
24.8
x | Employees | 26,700 |
| Yield 2024 * |
3.02% | Yield 2025 * |
3.27% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +1.79% | ||
| 1 week | +0.52% | ||
| Current month | +0.51% | ||
| 1 month | +10.43% | ||
| 3 months | +9.66% | ||
| 6 months | +12.84% | ||
| Current year | +6.74% |
1 week
295.49
311.48
1 month
295.49321.44
Current year
260.68329.72
1 year
215.32329.72
3 years
198.64329.72
5 years
170.56329.72
10 years
114.93329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 31/05/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 22/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 12-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 02/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 13/10/16 |
Robert Eckert
BRD | Director/Board Member | 69 | 31/12/02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +15.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/06/24 | 307.4 | +0.51% | 2,447,408 |
| 31/05/24 | 305.8 | +1.61% | 4,488,874 |
| 30/05/24 | 301 | +1.56% | 2,727,281 |
| 29/05/24 | 296.4 | -1.27% | 2,475,871 |
Delayed Quote Nasdaq, June 03, 2024 at 09:00 pm
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
29/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.74% | 164B | |
| +42.60% | 739B | |
| +32.34% | 598B | |
| -5.74% | 353B | |
| +17.79% | 318B | |
| +3.37% | 285B | |
| +16.47% | 240B | |
| +9.26% | 210B | |
| -5.07% | 206B | |
| +1.81% | 162B |
- Stock Market
- Equities
- AMGN Stock